Current Report Filing (8-k)
March 10 2017 - 7:48AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of the earliest
event reported): March 10, 2017 (March 9, 2017)
Valeant Pharmaceuticals International,
Inc.
(Exact Name of Registrant as Specified in
Its Charter)
British Columbia, Canada
|
001-14956
|
98-0448205
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
2150 St. Elzéar Blvd. West
Laval, Quebec
Canada H7L 4A8
|
|
(Address of Principal Executive Offices)(Zip Code)
|
|
|
514-744-6792
|
|
(Registrant’s telephone number, including area code)
|
(Former name or former address, if changed since last report)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
Pricing of Notes Offering
On March 10, 2017, Valeant
Pharmaceuticals International, Inc. (the “Company”) issued a press release announcing that on March 9, 2017 it
had priced its offering of $1.25 billion aggregate principal amount of 6.50% senior secured notes due 2022 and $2 billion
aggregate principal amount of 7.00% senior secured notes due 2024. The aggregate offering size of $3.25 billion reflects an
increase of $750 million from the previously announced offering size.
A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release announcing the pricing of the notes offering, dated March 10, 2017.
|
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
|
|
|
By:
|
/s/ Paul S. Herendeen
|
|
Name:
|
Paul S. Herendeen
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|
Date: March 10, 2017
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release announcing the pricing of the notes offering, dated March 10, 2017.
|
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2024 to Jun 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Jun 2023 to Jun 2024